In 2019, Roche achieved excellent operating results. I am delighted about the launches of our new cancer medicines Polivy and Rozlytrek, additional indications for Tecentriq and Kadcyla and priority review of risdiplam, our new medicine for a neurological disorder.
We have been committed to limiting our impact on the environment and climate change for many years, proactively seeking new, more sustainable technologies to achieve this goal as well as our business ambitions. Our emphasis on sustainability allows us to expand our business while limiting our ecological footprint.Read more about climate change on our sustainability page
André Hoffmann on climate change
At a glance
Roche continues driving one of this industry’s best product pipelines. In 2019, we invested about one fifth of the company’s sales to develop new tests and medicines for patients in need of new options. A leader in oncology, we are now also entering new disease areas with very low incidence rates. These include multiple sclerosis, haemophilia and neuroscience disesases.